CP101

BIOLOGICAL3 trials

Sponsors

Finch Research and Development LLC.

Conditions

ASDAutismAutism Spectrum DisorderAutistic BehaviorAutistic ThinkingC. DiffC. DifficileCDI

Phase 2

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

CompletedNCT03497806

Finch Research and Development LLC.CDI, C. Diff, C. Difficile +8

Start: 2018-05-01End: 2021-04-01Updated: 2022-08-30

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

WithdrawnNCT03829878

Finch Research and Development LLC.ASD, Autism, Autism Spectrum Disorder +8

Start: 2020-05-31End: 2021-12-31Updated: 2021-04-08

Phase 3

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

TerminatedNCT05153499

Finch Research and Development LLC.Recurrent C. Difficile Infection

Start: 2021-11-15End: 2023-02-24Updated: 2023-11-13